Oncology

A sudden collapse led to a rare cancer diagnosis for a NJ teen. His story of recovery highlights a therapy that targets tumors while sparing young minds.

The Korean biopharma giant is leveraging its biosimilar success to fund a major push into cutting-edge cancer therapies and advanced drug platforms.

Flashpoint Therapeutics appoints an FDA-approved drug developer as CSO, a strategic move to accelerate its groundbreaking structural nanomedicine platform.

Eagle Pharmaceuticals divests its unique post-op nausea drug to France's LXO Group, signaling a strategic pivot to oncology and critical care.

AstraZeneca's acquisition of Modella AI signals a major shift, embedding advanced AI directly into its cancer research to accelerate new treatments.

With $11.1M from industry giants, a Palo Alto startup is deploying an AI to automate prior authorizations and get cancer patients on therapy faster.

The AI health-tech leader achieved profitability and massive growth in 2025, expanding its reach to nearly 2,000 hospitals and doubling its life sciences arm.

Adimab's stellar 2025 reveals its crucial role as the hidden tech platform driving drug discovery for giants like Lilly and Regeneron.

NYU Langone and tech firm Tempus are launching a new protocol using serial DNA sequencing and AI to create hyper-personalized cancer treatments.

Erasca reports promising early data for its pan-RAS inhibitor, ERAS-0015, showing tumor shrinkage at low doses and shaking up the competitive landscape.

AbbVie inks a massive deal for a novel bispecific antibody, aiming to combine it with ADCs and enter the high-stakes race for solid tumor therapies.

TriSalus Life Sciences reports record 53% annual revenue growth, but a closer look reveals a complex financial picture for the oncology innovator.

With pivotal cancer drug data looming and a new nuclear supply chain, Bicycle Therapeutics is betting big on its novel platform. Will 2026 be its breakout year?

Cytek Biosciences reports preliminary 2025 revenue of $201M, beating estimates with a major Q4 growth surge ahead of its key J.P. Morgan presentation.

New clinical data suggests a more convenient option for cancer patients, potentially eliminating a return trip to the clinic for a key supportive care drug.

A novel drug that glues cancer proteins to the cellular trash system has entered human trials, offering new hope for rare diseases like Ewing sarcoma.

Promising Phase 2 data shows a new DNA immunotherapy for advanced melanoma, delivered via a needle-free jet injector, significantly improves patient outcomes.

Akari Therapeutics is advancing a new class of cancer drugs. Its unique PH1 payload kills tumors and activates the immune system, setting up a pivotal 2026.

The Oncology Institute promotes new CIO and CPO, signaling a strategic push into AI-driven care and robust talent management to dominate the market.

With the appointment of Dr. Stephen Eck, Flare Therapeutics signals a major push to advance its first-in-class cancer therapies targeting transcription factors.